Tags

Type your tag names separated by a space and hit enter

The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway.
Pharmazie. 2019 04 01; 74(4):239-242.P

Abstract

Diabetic nephropathy (DN) is a common cause of end-stage kidney disease (ESKD) all over the world. Sitagliptin, an inhibitor of DPP-IV plays a beneficial role in type 2 diabetic nephropathy. The purpose of this study was to explore the effect and mechanism of sitagliptin on renal injury in type 1 diabetic mice. Streptozotocin (STZ) induced type 1 diabetic mice were treated with oral administration of sitagliptin (15 mg/kg/ day) for 4 weeks. The results showed that sitagliptin treatment did not change the levels of blood glucose in STZ induced type 1 diabetic mice. Sitagliptin attenuates diabetic nephropathy by significantly inhibiting 24 h proteinuria, renal injury and fibrosis. Sitagliptin can inhibit the expression level of TGF-β1 and the other related fibrosis factors in renal tissue of type 1 diabetic mice while delaying the progression of type 1 diabetic nephropathy. These results indicated that sitagliptin treatment is potentially a new strategy for treating type 1 diabetic nephropathy.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30940309

Citation

Li, Luxin, et al. "The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Ameliorates Renal Injury in Type 1 Diabetic Mice Via Inhibiting the TGF-β/Smad Signal Pathway." Die Pharmazie, vol. 74, no. 4, 2019, pp. 239-242.
Li L, Lian X, Wang Z, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway. Pharmazie. 2019;74(4):239-242.
Li, L., Lian, X., Wang, Z., Zheng, J., Liu, J., Chu, Y., Teng, Y., & Zhang, Z. (2019). The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway. Die Pharmazie, 74(4), 239-242. https://doi.org/10.1681/ph.2019.8918
Li L, et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Ameliorates Renal Injury in Type 1 Diabetic Mice Via Inhibiting the TGF-β/Smad Signal Pathway. Pharmazie. 2019 04 1;74(4):239-242. PubMed PMID: 30940309.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway. AU - Li,Luxin, AU - Lian,Xu, AU - Wang,Zhilong, AU - Zheng,Junya, AU - Liu,Jieting, AU - Chu,Yanhui, AU - Teng,Yanjie, AU - Zhang,Zhen, PY - 2019/4/4/entrez PY - 2019/4/4/pubmed PY - 2019/6/15/medline SP - 239 EP - 242 JF - Die Pharmazie JO - Pharmazie VL - 74 IS - 4 N2 - Diabetic nephropathy (DN) is a common cause of end-stage kidney disease (ESKD) all over the world. Sitagliptin, an inhibitor of DPP-IV plays a beneficial role in type 2 diabetic nephropathy. The purpose of this study was to explore the effect and mechanism of sitagliptin on renal injury in type 1 diabetic mice. Streptozotocin (STZ) induced type 1 diabetic mice were treated with oral administration of sitagliptin (15 mg/kg/ day) for 4 weeks. The results showed that sitagliptin treatment did not change the levels of blood glucose in STZ induced type 1 diabetic mice. Sitagliptin attenuates diabetic nephropathy by significantly inhibiting 24 h proteinuria, renal injury and fibrosis. Sitagliptin can inhibit the expression level of TGF-β1 and the other related fibrosis factors in renal tissue of type 1 diabetic mice while delaying the progression of type 1 diabetic nephropathy. These results indicated that sitagliptin treatment is potentially a new strategy for treating type 1 diabetic nephropathy. SN - 0031-7144 UR - https://www.unboundmedicine.com/medline/citation/30940309/The_dipeptidyl_peptidase_4_inhibitor_sitagliptin_ameliorates_renal_injury_in_type_1_diabetic_mice_via_inhibiting_the_TGF_β/Smad_signal_pathway_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=0031-7144&volume=74&issue=4&spage=239&aulast=Li DB - PRIME DP - Unbound Medicine ER -